ArticleJAC-antimicrobial resistance2024
AmpC β-lactamases detected in Southeast Asian
Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Prevalence, Antimicrobial Resistance, and Resistance Gene Profiles of Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolated From Quails in Sylhet, Bangladesh.MicrobiologyOpen · 2026Article
- Characterization of the bacteriophage vB_KpnP_Henu1_3 lytic for K1Microbiology spectrum · 2026Article
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Fecal carriage, transferable β-lactam resistance, and efflux pump contribution in third-generation cephalosporin-resistantVeterinary world · 2026Article
- Should Cefoxitin Non-Susceptibility in Ceftriaxone-SusceptibleAntibiotics (Basel, Switzerland) · 2025Article
- Genomic insights into extended-spectrumJournal of medical microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Objectives: AmpC β-lactamases are neglected compared with ESBL as a cause of third-generation cephalosporin (3GC) resistance in Enterobacterales in low- and middle-income countries and the burden is unknown. The aim of this study was to investigate the presence of AmpC β-lactamase-producing Methods: Stored clinical isolates of Results: Of 126 isolates collected between 2010 and 2020, 31 (24.6%) and 16 (12.7%) were phenotypically AmpC and inducible AmpC positive by MASTDISCS testing, respectively. All inducible AmpC isolates were ceftriaxone susceptible and 97.7% of AmpC/inducible AmpC isolates tested against cefoxitin were resistant. Through WGS, 17 and eight different STs were detected for the AmpC/inducible AmpC Conclusions: Though uncommon, AmpC and inducible AmpC β-lactamases in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.